Unten finden Sie die vollständige Liste unserer Pressemitteilungen (Seite 23 von 28):
Ipsen's DIRECTION Phase IV trial meets primary and secondary endpoints comparing Dysport and Botox in upper limb spasticity. Key data for regulatory and QA teams.
FDA's CDER Antibacterial Drug Development Task Force targets trial design, approval pathways, and guidance revision. Key read for regulatory affairs leads with antibacterial pipeline assets.
Eton Pharmaceuticals takes U.S. commercialization of miltefosine (IMPAVIDO) from Knight Therapeutics effective September 26, 2026. Key supply chain implications for rare disease procurement teams.
Monopar Therapeutics publishes Phase 2 data showing ALXN1840 significantly improves copper balance in Wilson disease. Key findings for rare-disease regulatory and CMC teams.
Apothecon Pharma names Shyamakant Giri Group CEO to lead India-US operations including Navinta LLC, amid ongoing FDA scrutiny of Indian pharma facilities.
Regeneron's $2.32B Parabilis deal advances Helicon peptide-antibody conjugates, raising GMP, CMC, and CDMO capacity questions for the conjugate manufacturing sector.
ACG links dosage form and packaging design to medication non-adherence in elderly patients. Key implications for pharma R&D, formulation, and QA teams on ODTs, MUPS, and GMP risk.
Jupiter Neurosciences signs $100M term sheet for U.S. rights to PharmAla's NCE-designated ALA-002 MDMA compound amid shifting FDA and DEA psychedelic policy.
Roivant's $2.25B settlement ending Moderna LNP patent litigation signals ongoing IP risk for manufacturers using lipid nanoparticle delivery technology.
EMA's first quarterly report on EU 2030 clinical trial targets shows 40.5% of trials recruiting within 200 days. Key data for sponsors and regulatory leads.
Lupin receives tentative FDA approval for generic Revefenacin inhalation solution under the ANDA pathway. Key implications for inhalation manufacturing and US COPD market entry.
IGI nominates ISB 2301 as a solid tumor drug candidate, targeting an IND submission by end of 2026 and first-in-human studies in 2027.
Codexis presents first-of-kind phosphorothioate stereochemical control and starter-oligonucleotide-free siRNA synthesis at TIDES USA 2026 via ECO Synthesis platform.
CDER's C3TI opens early-engagement pathways on Bayesian statistics, SSDC, and pragmatic trials. Key implications for sponsors and regulatory affairs leads.
Madrigal presents eight Rezdiffra abstracts at EASL 2026 covering cardiovascular biomarkers, portal hypertension risk, and real-world MASH effectiveness data.
Phathom Pharmaceuticals presented 31 vonoprazan abstracts at DDW 2026, including 28 independent studies on GERD, H. pylori, and long-term safety outcomes.
Shaily Engineering secures tentative USFDA approval, Health Canada NOC, and Indian clearance for ShailyPen Neo autoinjector. Key read for combination-product and QA leads.
FDA CDER revises food-effect study guidance for IND/NDA submissions, splitting the 2002 document. Regulatory teams must cross-reference 2021 ANDA and 2022 NDA bioavailability guidances.
FDA's October 2025 ANDA pilot program fast-tracks generic drug reviews for U.S.-based manufacturers. What plant heads and QA directors need to assess now.
EMA's CHMP issued a negative trend opinion on MaaT013 (Xervyteg®). MaaT Pharma plans re-examination. Key read for regulatory affairs teams on CMA pathway risks.
Eledon Pharmaceuticals presents Phase 2 BESTOW long-term tegoprubart data at American Transplant Congress 2026, with implications for CD40L-targeted rejection prevention and BLA strategy.
Hansa Biopharma's €115M IDEFIRIX licensing deal with SERB Pharmaceuticals shifts European commercialization of imlifidase and triggers EMA post-approval change obligations.
A US federal jury found Takeda liable for a pay-for-delay agreement blocking Amitiza generic entry, awarding $2.5 billion in one of pharma's largest antitrust verdicts.
Boehringer Ingelheim India expands NIPER collaboration to Ahmedabad and Hyderabad, covering four campuses and integrating the opnMe open-innovation platform.
QIAGEN and NVIDIA integrate BioNeMo AI with biomedical knowledge bases to compress drug discovery timelines. Key implications for tech transfer and GMP readiness.
Infex Therapeutics reports positive Phase IIa data for RESP-X anti-virulence mAb in Pseudomonas-colonised NCFB patients, supporting quarterly dosing and Phase III.
Capricor's deramiocel faces an August 22, 2026 PDUFA date. Phase 3 HOPE-3 data support the DMD BLA. QA and manufacturing leads should assess allogeneic CGT readiness now.
Novartis presents Phase 1 actinium-225 PSMA-617 and Pluvicto data at ASCO 2026. CMC and plant heads should assess alpha-emitter manufacturing requirements now.
Cognition Therapeutics completed a Type B FDA meeting on May 20, 2026, to align on a registrational program for zervimesine in dementia with Lewy bodies psychosis.
Immix Biopharma reports 95% complete response rate in NEXICART-2 CAR-T trial. BLA submission targeted after March 2027 data readout. CMC implications for QA leads.
Pfizer advances its 25-valent pneumococcal conjugate vaccine to Phase 3 after strong infant Phase 2 data. Key implications for process validation, fill-finish, and FDA/EMA submissions.
Platinum Industries names Dr. Abhigyan Upadhyay to head its life sciences division, bringing 25+ years in regulated manufacturing and GMP environments.
Lilly's retatrutide achieved 30% weight loss across all doses in Phase 3 TRIUMPH-1. What it means for GLP-1 manufacturing capacity, fill-finish, and regulatory planning.
Haleon Canada's For The Assist campaign ties its consumer health portfolio to Canada Soccer, running across retail, digital, and experiential channels nationally.
FDA details NDA and ANDA approval pathways for OTC drugs, including required consumer behavior studies: label comprehension, self-selection, actual use, and human factors.
EMA accepts Teva and Medincell's MAA for TEV-'749 subcutaneous olanzapine LAI. Phase 3 SOLARIS data supports filing; SteadyTeq™ polymer platform raises new process validation demands.
Moleculin presents pooled Annamycin cardiac safety data at ASCO 2026: no significant LVEF change across 90 patients at doses exceeding anthracycline lifetime limits.
Regeneron's LINKER-AL2 trial reports 100% hematologic CR with linvoseltamab at 240 mg in second-line AL amyloidosis. Phase 2 registrational cohort ongoing.
Boehringer Ingelheim's ASCO 2026 zongertinib PRO data reinforces post-approval labeling strategy for HER2-mutant NSCLC and signals multi-indication CMC planning needs.
CHMP issues positive opinion for Allergan Aesthetics' Boey (trenibotulinumtoxinE) across 30 EEA markets. EC decision expected within months. Manufacturing and regulatory implications inside.
FDA's updated GDUFA Paid Facilities List warns generic drug manufacturers that FEI entry errors can trigger arrears classification. Verify your facility's payment status now.
Zentalis Pharmaceuticals reports 39% ORR and 7.3-month PFS for azenosertib plus paclitaxel in PROC at ASCO 2026. Key data for oncology drug development teams.
Syndax presents four Revuforj abstracts at ASCO 2026, covering post-transplant outcomes and PK data on CYP3A4 interactions and gastric acid agent compatibility.
The 79th World Health Assembly adopted resolutions on TB, steatotic liver disease, and haemophilia. Key pipeline and manufacturing capacity implications for pharma.
Hansa Biopharma's €115M IDEFIRIX licensing deal with SERB Pharmaceuticals triggers GMP compliance handoffs and supply chain reviews for European rare disease biologics.
Eli Lilly names Chandan S. Senior Director for Data Science and AI Engineering. Key implications for GMP quality systems, process validation, and regulatory submissions.
Reliance Life Sciences names Siva Sankar Mahamkali VP of Biosimilars Manufacturing Operations, signalling a push to meet GMP and regulatory demands in US and EU markets.
China's NMPA conditionally approves Boehringer Ingelheim's zongertinib for first-line HER2-mutant NSCLC. Dual U.S.-China approval creates parallel post-marketing obligations.
EMA's CHMP recommended eight medicines for EU approval in May 2026, including a conditional MA, three hybrid applications, and a biosimilar. Full regulatory roundup.
EMA's CHMP recommends nerandomilast (Jascayd) for IPF and PPF. Pirfenidone interaction restricts dose reduction, raising labeling and formulation compliance questions for EU manufacturers.
Regeneron's Otarmeni MAA accepted by EMA under Accelerated Assessment. Dual-AAV1 intracochlear gene therapy faces simultaneous FDA-EMA CMC scrutiny. Key read for QA and regulatory leads.
Alembic Pharmaceuticals secures USFDA approval for generic Levothyroxine Sodium tablets, therapeutically equivalent to AbbVie's Synthroid, for hypothyroidism treatment.
FDA's CDER PEPFAR tentative approval pathway sets the GMP and regulatory bar for ARV manufacturers. Two draft guidances are open for industry review.
Assembly Biosciences targets PBC and PSC with NTCP inhibitor ABI-6250 in a Phase 2 basket study planned for Q1 2027, following a pre-IND FDA meeting.
Venus Remedies secures SFDA approval for generic Plerixafor in Saudi Arabia, setting a regulatory precedent for complex oncology injectables in the GCC market.
GPACTS Mumbai Chapter Pharma AI & Data Congress 2026 will now take place on 10 June at Westin Mumbai Garden City, with a stronger focus on pharma tech and AI.
GPACTS Ahmedabad Chapter 2026 brings pharma manufacturing IT leaders together on 24 June in Ahmedabad to discuss CSV-to-CSA, MES, LIMS, and IT-OT security.
CHMP backs AbbVie's MAVIRET for acute HCV in EU adults and children. EC decision due Q3 2026. Key implications for labelling, batch release, and GMP compliance.
FDA CDER cleared 19 first generics in Q1 2026. Three Brivaracetam injectable approvals, Aprepitant, Norepinephrine, and two MDIs signal complex dosage form ANDA momentum.
FDA CDER approved 13 first-time generics in Q4 2025 across diabetes, MS, respiratory, and injectables. Key ANDA holders include Watson, Sandoz, Apotex, and Amneal.
FDA approved Daiichi Sankyo's Datroway for metastatic TNBC on May 22, 2026. Project Orbis review involved 5 agencies. Key ADC manufacturing and CMC implications.
CHMP recommends EU approval for Novo Nordisk's oral semaglutide 25 mg (Wegovy pill), the first oral GLP-1 for obesity. EU launch targeted H2 2026.
CHMP issues positive opinion for Boehringer Ingelheim's nerandomilast in IPF and PPF. EU Commission decision expected within two months following Phase III FIBRONEER data.
FDA reclassifies Differin Epiduo (adapalene/benzoyl peroxide) to OTC under NDA 220736. Key GMP, labeling, and validation implications for manufacturers.
Venus Remedies secures Saudi SFDA approval for Plerixafor injectable. Key implications for GCC market entry, site qualification, and dossier strategy for Indian pharma manufacturers.
Lupin secures NMPA approval for Oseltamivir oral suspension in China via Yabao Pharmaceuticals, highlighting the local-partner model for Indian generics market access.
Encoded Therapeutics aligns with FDA on ETX101 pivotal design via RMAT pathway. ENDEAVOR Part 2 enrollment targets end of 2026, data readout in 2027.
FDA approved a required boxed warning update for Moderna's SPIKEVAX on June 25, 2025, covering myocarditis and pericarditis risk. Key compliance implications for QA and regulatory teams.
FDA approves Gilead's Hepcludex for chronic HDV infection under Accelerated Approval. Key implications for QA, regulatory affairs, and injectable biologic manufacturing teams.
CHMP recommends EU approval of Novo Nordisk's Wegovy 7.2 mg single-dose pen. Q3 2026 launch planned. Key CMC, EU MDR, and device validation implications for QA leads.
CHMP backs Merck's KEYTRUDA combo for bladder cancer. European Commission decision expected Q3 2026. Key implications for EU regulatory and QA teams.
Lilly's Foundayo shows significant weight reduction at 72 weeks in seniors. What the oral GLP-1 result means for CMC submissions, excipient sourcing, and scale-up.
AbbVie's MAVIRET receives positive CHMP opinion for acute HCV in the EU. Regulatory implications for indication expansion and post-approval change management.
Anupam Rasayan acquires 43.3–48.2% of Bliss GVS Pharma. QA and regulatory leads face GMP alignment and multi-jurisdiction notification challenges post-close.
EMA accepts TEV-749 marketing application from Teva and Medincell. What the BEPO depot platform means for CMC review and LAI manufacturing precedent in Europe.
ACG showcased Blister X, Karton X, and ProTab 700 as a unified OSD manufacturing system at Interpack 2026, targeting downtime reduction and SKU complexity.
Enveric Biosciences reports a Phase I safety milestone for EB-003 neuroplastogen. Key manufacturing and formulation implications for CDMOs and QA directors.
Alembic Pharmaceuticals names Dr. Ramesh Juneja Head of India Business. What the appointment means for domestic generics operations, CDSCO compliance, and supply-chain alignment.
Amgen appoints Madhur Sarin to lead its AI and Data Science COE, embedding scalable AI platforms into manufacturing quality, regulatory submissions, and enterprise ops.
Novartis presents late-breaking Phase III IgAN data for Vanrafia and Fabhalta at ERA 2026. Key implications for EMA submissions, CMOs, and supply chain planners.
Novo Nordisk's POSEIDON study of 18,904 patients finds cardiovascular inflammation in 2 in 5 high-risk CVD patients, signalling a first-in-class drug opportunity.
China's NMPA approves Boehringer Ingelheim's HERNEXEOS for unresectable NSCLC. Key GMP, supply chain, and post-approval compliance implications for plant heads and QA leads.
60 Degrees Pharmaceuticals reports early enrollment in its tafenoquine babesiosis trial, with interim analysis now projected for early July 2026 across five U.S. sites.
Ionetix becomes the first commercial manufacturer with FDA ANDA approval for Ga-68 gozetotide. A three-hour expiry window raises GMP and distribution complexity.
EMA recommends conditional EU marketing authorisation for Novartis Vijoice in PROS. Key post-marketing, GMP, and pharmacovigilance obligations explained for QA and regulatory leads.
Mogo Moringa LLC recalls two capsule lots after FDA coordination despite negative Salmonella lab results, a supplement GMP compliance case study for QA directors.
EMA's CHMP issued a negative trend opinion on MaaT Pharma's Xervyteg MAA. A re-examination procedure follows the June 2026 formal vote. Key read for EU regulatory leads.
FDA's import alert 66-80 targets non-compliant GLP-1 APIs at the border. QA directors must audit supplier qualification programs and cold-chain SOPs now.
FDA eliminates embryofetal toxicity REMS for ambrisentan, macitentan, and aprocitentan after 20 years of post-market data. Bosentan and sparsentan REMS modified.
FDA's updated domperidone guidance documents cardiac and neuropsychiatric risks. QA and regulatory teams with active expanded access INDs must review adverse event protocols.
Insulet issues voluntary correction for 7M Omnipod pods after cannula tear defect causes insulin under-delivery. 24 serious adverse events reported. CAPA measures implemented.
Total Nutrition Inc. recalls TNVitamins and Doctor's Pride moringa capsules after FDA and CDC flag Salmonella risk. Key lessons for pharma supplier qualification.
Zealand Pharma presents Phase 2 ZUPREME-1 petrelintide data at ADA 2026. Key readouts on amylin analog efficacy and safety with implications for peptide manufacturing scale-up.
ImmuPharma initiates IND-enabling activities for Kapiglucagon via FDA 505(b)(2) pathway. Key implications for CMC strategy and peptide drug development timelines.
Intravacc is now a French CIR-approved private research organization for 2025–2027, enabling French pharma partners to declare outsourced vaccine R&D under the tax credit framework.
3PBIOVIAN commissions a second 2,000 L single-use bioreactor, expanding its mammalian GMP platform from 50 L to commercial scale for recombinant protein manufacturing.
Jupiter Neurosciences opens enrollment in Phase 2a RESET trial for JOTROL™, a micellar resveratrol formulation, following FDA IND clearance in November 2025.
Atea Pharmaceuticals Phase 1 DDI data show BEM/RZR requires no dose adjustments with omeprazole or rosuvastatin, supporting HCV regulatory submission strategy.
Tonix Pharmaceuticals publishes Phase 1 data for Fc-modified anti-CD40L mAb TNX-1500. Phase 2 kidney transplant study at MGH targeted H2 2026 pending FDA IND clearance.
FDA preliminary trial data show tofacitinib raises serious cardiac and cancer risk at both doses. Labeling updates and compliance obligations for Pfizer expected.
FDA requires Boxed Warning revisions for Xeljanz, Olumiant, and Rinvoq citing cardiovascular, cancer, thrombosis, and death risks. Labeling compliance obligations for regulatory teams.
FDA's ADF framework sets the evidentiary and labeling bar for branded and generic opioid manufacturers. Key guidance, approved products, and compliance implications covered.
CDT Equity completes global IP coverage for AZD5904 following Canadian patent grant, advancing licensing talks in a $4.4B male infertility market with no approved therapies.
Eli Lilly acquires Curevo for up to $1.5B as part of a $3B+ vaccine push. Key implications for biologics manufacturing, fill-finish, and cold-chain operations.
Sun Pharma's Phase II trial in laCSCC achieves 50% response rate. What it means for regulatory submissions, biologics manufacturing, and process validation timelines.
FDA requests removal of the statin pregnancy contraindication, triggering mandatory labeling revisions across all branded and generic statin products under 21 CFR Part 201.
All TIRF medicines discontinued Sept 30, 2024, but REMS obligations remain active for NDA/ANDA holders. Key compliance implications for regulatory affairs teams.
Abbott secures CE Mark for Libre Duo, the first continuous dual glucose-ketone sensor. Key regulatory and integration implications for device and QA teams.
FDA ends the Clozapine REMS effective February 2025, directing manufacturers to submit formal elimination modifications and revise prescribing information. Key steps for regulatory teams.
FDA finalizes ICH M7(R2) guidance on mutagenic impurity assessment, updating acceptable intake calculations and Q&A resources for drug manufacturers and QA teams.
Dyne Therapeutics submits a BLA for z-rostudirsen under accelerated approval following DELIVER trial data. Sartorius opens €140M CGT manufacturing center in Germany.
Zentalis Pharmaceuticals names Shannon Campbell to its board and Sarah Kelly as SVP of Commercial Strategy, building launch infrastructure for azenosertib in ovarian cancer.
FDA approved AbbVie's Decnupaz (pivekimab sunirine-pvzy) for BPDCN on May 27, 2026. Key GMP, CMC, and pharmacovigilance implications for ADC manufacturers.
Shilpa Biologicals MD Madhav Bhutada warns single-CDMO dependence can increase biopharma development costs by up to 40% and stall clinical timelines.
Asahi Kasei licenses a site-specific DAR-control ADC platform for single- and dual-payload conjugates, with implications for process validation and CMC filings.
Novo Nordisk presents late-stage semaglutide and GLP-1 pipeline data at ADA 2026. Key implications for CDMO capacity, API supply chains, and process validation planning.
FDA grants Priority Review to Sanofi's venglustat NDA for Gaucher disease type 3. PDUFA date set for 25 November 2026. Phase 3 LEAP2MONO data supports filing.
Lupin's Ankleshwar site receives a U.S. FDA EIR following a product-specific pre-approval inspection in March 2026, clearing a key GMP compliance checkpoint.
Anaveon reports ANV600 Phase 1 results at ASCO 2026: 42% disease control in monotherapy, CR in NSCLC. Company seeks global oncology partners post-strategic pivot.
Quotient Sciences doses Phase I subjects with an AI-designed oral formulation after MHRA approval. Key implications for QA, CMC strategy, and CDMO development.
FDA CDER finalizes bioequivalence guidance for ANDA submissions with pharmacokinetic endpoints. Generic drug manufacturers must review BE protocols against the 2026 final text.
FDA's CDER finalizes bioequivalence statistical guidance replacing the 2001 framework. NDA and ANDA sponsors must update BE protocols and submission packages now.
SciSparc's NeuroThera Labs secures conditional TSX approval to acquire 54% of CliniQuantum, a quantum Monte Carlo clinical analytics firm, for ~$9.46M in shares.
FDA requires class-wide boxed warnings and Medication Guides for nearly 400 opioid and benzodiazepine products. Key labeling compliance implications for QA and regulatory teams.
WHO recommends Regeneron's maftivimab for investigational Bundibugyo ebolavirus trials in DRC and Uganda. Key implications for regulatory and supply chain leads.
FDA approved AstraZeneca's Imfinzi (durvalumab) plus BCG for BCG-naïve high-risk NMIBC on May 28, 2026. Key facts for QA, regulatory, and pharmacovigilance teams.
Allogene Therapeutics names R&D chief Zachary Roberts as President, succeeding co-founder David Chang. Key implications for allogeneic cell therapy manufacturing and CMC strategy.
Eli Lilly's full PBM coverage for its GLP-1 obesity portfolio will pressure CMO capacity, API supply chains, and GMP compliance. Key implications for plant heads and QA directors.
EMA's ETF directs COVID-19 vaccine MAHs to reformulate for the XFG variant ahead of the 2026/2027 campaign. Key submission and manufacturing change obligations explained.
WHO advisory groups prioritize MBP134, remdesivir, and obeldesivir for Bundibugyo Ebola clinical trials. Key GMP and regulatory implications for CDMOs and manufacturers.
WHO identifies a 160-country regulatory gap on nicotine pouches and calls for flavour bans and advertising restrictions as youth e-cigarette use rises globally.
WHO Director-General addresses Ituri province directly as Ebola returns to DRC, with 90%+ of cases in the region and conflict complicating outbreak response.
AbbVie's expanded VENCLYXTO EU label covers three new first-line CLL combinations, requiring multi-market labeling, batch release, and supply chain updates across 30-plus EEA markets.
Australia's TGA revises its Authorized Prescriber framework for psilocybin and MDMA, broadening workforce and settings. What it means for GMP manufacturers supplying the market.
Johnson & Johnson submits EMA application for teclistamab in earlier myeloma lines after Phase 3 MajesTEC-9 shows 71% PFS and 40% OS benefit vs standard of care.
FDA's May 2026 draft guidance introduces single-species testing and weight-of-evidence NHP alternatives for oncology biologics. Comment deadline July 30, 2026.
FDA approves Cefepime/Zidebactam Injection. Sterile manufacturing facilities and QA teams face new process validation and sterility assurance demands for this novel IV antibiotic.
FDA finalizes ICH Q9(R1) QRM guidance, targeting subjectivity, formality gaps, and product availability risks. Key updates for QA and regulatory teams.
Pfizer's CROWN trial reports seven-year PFS data for LORBRENA in ALK-positive NSCLC, with implications for manufacturing scale-up, supply planning, and ICH Q1A stability protocols.
AstraZeneca's Phase III anselamimab trial in cardiac AL amyloidosis yields mixed results. Key implications for process validation, regulatory strategy, and biologic supply planning.
Merck's calderasib receives FDA Breakthrough Therapy designation in KRAS G12C lung cancer. Key CMC and manufacturing readiness implications for QA and regulatory leads.
FDA approves AstraZeneca's Imfinzi combination for bladder cancer after 60.7-month trial. Key GMP, ICH Q10, and process validation implications for biologics manufacturers.
Lupin secures FDA ANDA approval for a generic colonoscopy prep drug with 180-day first-to-file exclusivity, signalling a disciplined Hatch-Waxman strategy.
Lupin secures FDA ANDA approval for generic Sutab Tablets with 180-day exclusivity. Key implications for manufacturing scale-up and GI generics pipeline competition.
Ascentage Pharma reports 23.5% ORR for alrizomadlin plus lisaftoclax in pediatric sarcomas at ASCO 2026, with China NMPA SPARK Plan inclusion for accelerated development.
Pfizer's $10B deal with Innovent Biologics covering 12 antibody drugs creates GMP harmonisation and tech transfer demands for CMOs and QA teams globally.
AstraZeneca gained 11 CDSCO approvals in FY26 as India revenue rose 33% to Rs. 22.76 billion. What it means for regulatory planning and CDSCO timelines.
Sanofi's AccelRare gains Class A medical device classification in India. What the regulatory outcome means for pharma companies expanding AI digital health tools in emerging markets.
Samsung Bioepis launches OPUVIZ, its aflibercept biosimilar referencing Eylea, across Europe, its fifth directly commercialized biosimilar. Key GMP and market access implications.
FDA grants Zydus priority review for saroglitazar NDA in primary biliary cholangitis with a November 27, 2026 PDUFA date. Key implications for QA and regulatory teams.
Intravacc and Primrose Bio renew their partnership to offer conjugate vaccine developers integrated GMP manufacturing and PeliCRM197® carrier protein supply through Phase I/II.
Curium commits €32M at Saclay to build a GMP 177Lu-PSMA-I&T production line for European RLT demand. Key read for plant heads and QA directors.
Novartis presents 31 EULAR 2026 abstracts covering secukinumab REPLENISH Phase III, CAR-T rap-cel, and ianalumab across autoimmune indications. GMP and regulatory implications.
Idorsia's high-dose Phase 1 cohort confirms IgG immunogenicity for its synthetic glycan C. difficile vaccine. GMP and process validation implications for incoming partners.
Roche moves enicepatide and petrelintide into Phase III simultaneously and initiates a combination trial, raising CMC and manufacturing scale-up challenges for GLP-1-class biologics.
Idorsia's PRECISION Phase 3 data show aprocitentan delivers sustained UACR reductions through Week 36 in resistant hypertension, informing sNDA and label expansion strategy.
Wockhardt's ZAYNICH wins FDA approval for complicated UTIs, outperforming meropenem 89% vs 68.4% in Phase 3 ENHANCE-1 trial.
Novartis ASC4FIRST 144-week data shows Scemblix superiority over all TKIs in newly diagnosed CML. Key implications for CMC filings, process validation, and supply planning.
Ardena names Ariane de Ganck Chief Scientific Officer, unifying CMC regulatory affairs and aseptic manufacturing leadership across its CDMO network.
Renexxion and Dr. Falk Pharma advance naronapride into Phase 3 pivotal studies for gastroparesis, targeting a US NDA filing and parallel EU approval.
IDEAYA Biosciences and Servier target H2 2026 NDA filing under FDA RTOR after darovasertib combination meets Phase 2/3 PFS endpoint in metastatic uveal melanoma.
T-CURX acquires Pantherna's LNP delivery platform, accelerating non-viral in vivo CAR-T clinical translation by one year. Key implications for ATMP CDMOs and GMP readiness.
LIXTE Biotechnology exits pharma to become an AI energy infrastructure platform. Denham Capital founder Stuart Porter joins the board. Clinical assets to be divested.
FDA's OGD 2023 Annual Report details GDUFA III research reshaping bioequivalence standards and complex ANDA pathways. 956 ANDAs approved, including 90 first generics.
CSL Behring's IDELVION approval history under FDA STN 125582 offers QA and regulatory leads a benchmark for albumin fusion protein lifecycle management.
FDA CBER approved a labeling supplement for LFB S.A.'s SEVENFACT in June 2024. Key reference for regulatory teams tracking recombinant coagulation factor biologics.
FDA clears AstraZeneca's Imfinzi plus BCG for high-risk NMIBC, the first US-approved immunotherapy combination for this indication. CMC and supply implications inside.
Marksans Pharma acquires Netherlands-based QliniQ B.V., gaining EU distribution and market-access capabilities. Key implications for GMP integration and regulatory alignment.
Evotec SE names AstraZeneca's former AI lead Rui Wang as EVP Head of Global In Silico and AI, embedding computational science across R&D and biologics manufacturing.
Moderna and Merck's personalized mRNA cancer vaccine shows five-year survival signal in melanoma. What the data means for GMP scale-up and regulatory submissions.
CEPI commits up to $50M to fund Moderna's mRNA Ebola vaccine through preclinical and Phase 1 trials. Key manufacturing and regulatory implications for pharma ops teams.
CellCarta and Leica Biosystems expand their companion diagnostic partnership, integrating GMP manufacturing and biomarker testing for faster CDx regulatory submissions.
FDA accepts Roche's giredestrant NDA under Priority Review for early-stage ER-positive breast cancer. PDUFA date: 30 November 2026. Phase III data showed 30% iDFS reduction.
European Commission approves AbbVie's atogepant for acute migraine treatment, creating dual-indication supply and regulatory obligations across EU markets.
Optimi Health completes a GMP psilocybin production run under a single Health Canada DEL, supplying Australia's TRD market and US and European clinical trials.
FDA grants Pasithea Therapeutics Orphan Drug Designation for PAS-004 in ALS, unlocking tax credits, fee exemptions, and seven-year market exclusivity potential.
Telix and United Imaging sign U.S. MOU to standardize theranostics workflows, targeting protocol-driven imaging consistency and AI tools for TLX101-Px programs.
Achieve Life Sciences adds Jeffrey Farrow and Reid Waldman MD to its board as cytisinicline NDA resubmission approaches, signaling pre-approval commercial readiness.
Karyopharm's SENTRY Phase 3 trial meets primary endpoint with 49.8% SVR35 for selinexor-ruxolitinib vs 28% for ruxolitinib alone. Regulatory and manufacturing implications examined.
FDA cited HealthPartners Neuroscience Center for GLP mixture uniformity failures under 21 CFR 58.31(d). Key read for QA directors and regulatory affairs leads.
FDA's June 2026 draft guidance lets gene therapy sponsors leverage platform CMC and prior data to streamline submissions. Key implications for QA and RA teams.
Sapience Therapeutics publishes Phase 2 window-of-opportunity data for lucicebtide (ST101) plus chemoradiation in newly diagnosed GBM. Key efficacy and safety findings reviewed.
AB Science's FDA-authorized masitinib ALS Phase 3 trial and AB8939 AML programme advance. Stonegate assigns €4.25/share DCF valuation after FY2025 results.
Cipla relocates senior executive Taher Karampurwala to Saudi Arabia to lead Middle East operations, raising GMP and regulatory compliance implications for Gulf market expansion.
Alkem's DCGI-approved semaglutide pre-filled syringe at Rs. 350 raises fill-finish, cold-chain, and regulatory compliance questions for Indian GLP-1 manufacturers.
Aragen achieves commercial GMP readiness for Renaissance Pharma's anti-GD2 mAb in 9 months. Key implications for CMC, process validation, and BLA submission.
Novo Nordisk's oral semaglutide launches in the UAE, the first market outside the US. EMA review ongoing; H2 2026 launches confirmed. Manufacturing implications for GLP-1 oral dose.
Johnson & Johnson's nipocalimab met Phase 2 primary endpoint in SLE at Week 24 with sustained 52-week response. Phase 3 underway; CMC and BLA implications explored.
UroGen and Teva settle JELMYTO patent litigation, allowing generic entry in 2030 while preserving most of the drug's patent protection.
Lungpacer Medical names Steven Pfanstiel as CFO to lead AeroPace System commercialization, backed by 25 years of healthcare finance expertise.
Cabaletta Bio reports 83% registrational endpoint rate for rese-cel in dermatomyositis at EULAR 2026, with JDM BLA planned for 2H27 and SSc pivotal study in 4Q26.
Kura Oncology's darlifarnib posts 67% ORR in pancreatic cancer at ASCO 2026. New platform trial design raises CMC and supply chain planning considerations.
Akums gains EDQM Certificate of Suitability for Cefpodoxime Proxetil, opening a Ph. Eur.-compliant API supply route for European finished-dose manufacturers.
Servier acquires Edgewise Therapeutics' muscular dystrophy pipeline for $2.65B. Key manufacturing, process validation, and regulatory integration implications for QA and plant heads.
Medicus Pharma files Phase 2b protocol with FDA for SkinJect in Gorlin Syndrome, pursuing NDA support and orphan drug designations for this rare skin cancer indication.
IDEAYA Biosciences and Roche launch a jointly governed Phase 1 combination study of IDE892 and RG6505 in MTAP-deleted PDAC. Key GMP and IND implications inside.
FDA CDER accepts first ISTAND in silico DDT, an AI-Driven Digital Liver Model for DILI prediction. Key implications for preclinical and regulatory teams.
Lupin and Natco secure FDA approval for generic Eribulin Mesylate Injection 1 mg/2 mL, bioequivalent to Eisai's Halaven, intensifying competition in US oncology injectables.
Cadrenal Therapeutics receives FDA End-of-Phase 2 guidance supporting a single pivotal Phase 3 trial for CAD-1005 in Heparin-Induced Thrombocytopenia.
EMA's Emergency Task Force and AMA identify six Bundibugyo virus candidates and launch joint developer discussions following WHO's PHEIC declaration in May 2026.